United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $534.66, for a total transaction of $5,079,270.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $173,466,694.38. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $10.03 during trading on Monday, reaching $543.15. The company had a trading volume of 495,524 shares, compared to its average volume of 556,959. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35. The stock has a market cap of $23.30 billion, a PE ratio of 19.43, a PEG ratio of 3.81 and a beta of 0.49. The business’s 50 day moving average price is $513.64 and its 200-day moving average price is $540.06.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the business earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Janus Henderson Group PLC raised its holdings in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Jupiter Topco LLC bought a new stake in United Therapeutics during the second quarter worth about $450,140,000. Swedbank AB raised its holdings in United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its position in United Therapeutics by 0.8% during the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company’s stock valued at $183,306,000 after purchasing an additional 2,383 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Jefferies Financial Group reissued a “buy” rating and issued a $728.00 target price on shares of United Therapeutics in a research note on Wednesday, October 14th. Royal Bank Of Canada boosted their target price on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Leerink Partners upped their price target on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday. Finally, JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $650.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.